Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ocular hypertension or primary open-angle glaucoma in each eye
Requires IOP-lowering therapy in both eyes
Visual acuity score of 20/100 or better in each eye
You may not be if
Experienced significant weight change (over 10 pounds) within 60 days
History of alcohol or drug addiction
History of migraines or frequent headaches
Anticipated wearing of contact lenses during the study
Required chronic use of ocular medications during study
Eye surgery within 6 months
Use of systemic beta blockers (eg, atenolol, propranolol) within 2 months
Use of oral, intramuscular, intravenous corticosteroids within 21 days
Use of ophthalmic corticosteroids within 2 months
Clareo Health | Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
